Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

Abstract

Lung function improvements with tiotropium Respimat(®) add-on to medium-dose ICS were sustained and similar for once-daily 5 μg and twice-daily 2.5 μg, supporting tiotropium Respimat(®) 5 μg as a once-daily bronchodilator that provides efficacy over the whole 24-h dosing interval in patients with symptomatic asthma. ClinicalTrials.gov identifier: NCT01152450.

Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status

“…In studies of patients with mild or moderate disease receiving maintenance treatment with ICS alone, tiotropium improved lung function and asthma control [5,7,8,10,11,13], and similar efficacy was confirmed in three studies comparing the efficacy of tiotropium with salmeterol as add-on to ICS [5,7,10]. In patients with more severe asthma e symptomatic despite treatment with ICS (!800 mg budesonide or equivalent) plus a LABA e a short-term trial demonstrated significant improvements in lung function following tiotropium add-on therapy [6].…”

Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial

“…1,8 Clinical studies in adults have demonstrated that tiotropium administered through the Respimat Soft Mist inhaler (Boehringer Ingelheim, Ingelheim am Rhein, Germany) is an effective and well-tolerated add-on treatment to at least ICS maintenance therapy in patients with mild, moderate, or severe symptomatic asthma. [9][10][11][12][13][14][15][16] The 2015 revision of the Global Initiative for Asthma strategy includes 5 mg of tiotropium administered through the Respimat device as an option for addition to ICS plus a LABA treatment at steps 4 and 5 in adults with a history of 1 Phase II studies in adolescents and children have shown similar lung function benefits to those observed in adults when tiotropium Respimat is added to at least ICSs. 17,18 We present results from a 1-year phase III study designed to examine the efficacy and safety of 2 doses (5 and 2.5 mg) of oncedaily tiotropium Respimat compared with placebo when added to background treatment with ICS maintenance therapy with or without a leukotriene receptor antagonist (LTRA) in adolescents with moderate symptomatic asthma.…”

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?

“…Both once-daily 5 µg and twice-daily 2.5 µg provided significant and comparable 24-h bronchodilation (compared with placebo: once-daily 5 µg, 158 mL; twice-daily 2.5 µg, 149 mL (both p<0.01)), with improvements in peak FEV1, trough FEV1, and morning and evening PEF that were also statistically significant with both dosing regimens (table 1). Tiotropium add-on therapy significantly improved mean ACQ-7 score (compared with placebo: once-daily 5 µg, −0.274 ( p<0.01); twice-daily 2.5 µg, −0.190 ( p<0.01)) and adverse events were comparable between all treatment regimens (table 2) [57].…”